TargetRx Atlas

MRNA basic information

  • mRNA ID:ENST00000589042
  • Gene Name:TTN
  • mRNA database:Ensembl
  • mRNA expression :down-regulated
  • mRNA Method:RT-PCR
  • mRNA Pathway:NA
  • Evidence:predicted
  • (mRNA-drug)

Drug basic information

  • Drug ID:NA
  • Drug Name:NA
  • Drug Method:NA

Disease basic infommation

  • Disease:glioma
  • Tissue:the human glioma cell lines (U87, A172, LN229 and U251) and normal human astrocytes (NHA)

Other information

  • Title:lncRNA TTN-AS1 upregulates RUNX1 to enhance glioma progression via sponging miR-27b-3p.
  • Journal:Oncology reports
  • Published:2020
  • PubMed ID:32705233
  • Abstract:Long non-coding RNAs (lncRNAs) contribute to the tumorigeneses of numerous types of cancer, including glioma. The present study was designed to unveil a novel lncRNA functioning in glioma and explore the underlying mechanisms. lncRNA titin-antisense RNA1 (TTN-AS1), miR-27b-3p and Runt-related transcription factor 1 (RUNX1) expression in glioma tissues and cell lines was estimated by RT-qPCR. Si-TTN-AS1 was transfected into glioma cell lines (U251 and LN229), and CCK-8 assay, flow cytometry, wound healing and Transwell assays were applied to estimate the function of TTN-AS1 in glioma cells. miR-27b-3p inhibitor was used to explore the mechanisms. The results revealed that TTN-AS1 was highly expressed in glioma specimens and cell lines. Downregulation of TTN-AS1 inhibited the proliferation, migration and invasion of the glioma cells, as well as increased the rate of apoptosis. In vivo, the tumor growth was also inhibited by TTN-AS1 depletion in nude mice. Furthermore, we revealed that TTN-AS1 exerted oncogenic effects via sponging miR-27b-3p and thereby positively regulating RUNX1 expression. In conclusion, the present study supported that TTN-AS1 acts as an oncogene in glioma by targeting miR-27b-3p to release RUNX1. This finding may contribute to gene therapy of glioma.